Get In Touch

Rare Neurodegenerative Disease Treatment Market to Reach Valuation of US$ 116.3 Bn by 2030: Transparency Market Research

Rare Neurodegenerative Disease Treatment Market: Introduction

According to the report, the global rare neurodegenerative disease treatment market was valued at US$ 67 Bn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Various types of neurological disorders are epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular diseases, and others. The different types of drug class to treat neurology disorders are anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others. In terms of indication, the global rare neurodegenerative disease treatment market has been classified into multiple sclerosis (MS), Alzheimer’s disease, Parkinson's disease, acute migraine, autism, narcolepsy, amyotrophic lateral sclerosis (ALS), attention deficit hyperactivity disorder (ADHD), spinal muscular atrophy, Tourette syndrome, Huntington's disease, and others. The multiple sclerosis (MS) segment captured the largest market share in 2019. The segment is expected to be driven by rise in number of patients with multiple sclerosis and increase in awareness about the disorder.

Based on drug class, the global rare neurodegenerative disease treatment market has been categorized into neurotransmitter agents, neuroprotective agents, biologics, and others. The neuroprotective agents segment held major share of the global market in 2019. In terms of distribution channel, the global rare neurodegenerative disease treatment market has been divided into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment accounted for the leading share of the market in 2019. Large inventory maintained by hospitals and availability of essential drugs at hospital pharmacies are likely to drive the segment.

Rare Neurodegenerative Disease Treatment Market: Prominent Regions

North America held a major share of the global rare neurodegenerative disease treatment market in 2019. Recent product approvals & launch of new drugs and presence of prominent pharmaceutical companies offering therapeutic products for the treatment of rare neurological disorders are key factors driving the market in the region. Increase in healthcare expenditure also contributes to the growth of the market in North America. Europe held the second largest share of the global rare neurodegenerative disease treatment market in 2019. The growth of the rare neurodegenerative disease treatment market in the region can be attributed to the rise in the number of patients with rare neurological conditions and increase in R&D expenditure.

Rare Neurodegenerative Disease Treatment Market: Key Players

Leading players are expanding their footprint to strengthen their positions in the global rare neurodegenerative disease treatment market. Promising drug candidates in pipeline and increase in research & development efforts by big pharmaceutical companies are likely to present lucrative opportunities in the global rare neurodegenerative disease treatment market. Hence, manufacturers engage in new product development, collaborations, and distribution to gain market share. Key players operating in the global rare neurodegenerative disease treatment market include Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Global Rare Neurodegenerative Disease Treatment Market: Segmentation

Rare Neurodegenerative Disease Treatment Market, by Indication

  • Multiple Sclerosis (MS)
  • Alzheimer’s Disease
  • Parkinson's Disease
  • Acute Migraine
  • Autism
  • Narcolepsy
  • Amyotrophic Lateral Sclerosis (ALS)
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Spinal Muscular Atrophy
  • Tourette Syndrome
  • Huntington's disease
  • Others

Rare Neurodegenerative Disease Treatment Market, by Drug Class

  • Neurotransmitter Agents
  • Neuroprotective Agents
  • Biologics
  • Others

Rare Neurodegenerative Disease Treatment Market, by Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Rare Neurodegenerative Disease Treatment Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific     
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

7 of 10 large enterprizes view our ToC to take the right decision.

View Report ToC